Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluspidine
- Development stage
- Unknown
- Lead developer
- Helmholtz-Zentrum Dresden-Rossendorf
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fluspidine is a spirocyclic piperidine derivative developed as a positron emission tomography (PET) tracer for the imaging of sigma-1 (σ1) receptors. Both (S)- and (R)-enantiomers labeled with fluorine-18, known as (S)-[18F]fluspidine and (R)-[18F]fluspidine, have been evaluated in humans for PET imaging. Fluspidine exhibits very high affinity and selectivity for the sigma-1 receptor over the sigma-2 receptor, making it valuable for non-invasive quantification of sigma-1 receptors in the brain, which are implicated in neuropsychiatric and neurodegenerative disorders[4][8].
- Other names
- (S)-[18F]fluspidine(R)-[18F]fluspidine[18F]fluspidine
02
Targets
SIGMAR1 (Sigma non-opioid intracellular receptor 1)
Beyond the preview
Go deeper on fluspidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluspidine.